Tafenoquine 100mg

DRUG2 trials

Sponsors

GlaxoSmithKline, 60 Degrees Pharmaceuticals LLC

Conditions

Chronic BabesiosisMalaria, Vivax

Phase 2

Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse

CompletedNCT01376167

GlaxoSmithKlineMalaria, Vivax

Start: 2014-04-24End: 2016-11-18Updated: 2018-04-23

B-FREE Chronic Babesiosis Study

RecruitingNCT06656351

60 Degrees Pharmaceuticals LLCChronic Babesiosis

Start: 2025-11-18End: 2027-09-30Target: 40Updated: 2025-11-21

Related Papers

Single-Dose Tafenoquine to Prevent Relapse of <i>Plasmodium vivax</i> Malaria

New England Journal of Medicine2019-01-16277 citations

A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria

PLoS ONE2017-11-0936 citations

Abrogation of red blood cell G6PD enzyme activity through Heat treatment: development of survey material for the UK NEQAS G6PD scheme.

2017-03-204 citations

Estimation of the Antirelapse Efficacy of Tafenoquine, Using <i>Plasmodium vivax</i> Genotyping

The Journal of Infectious Diseases2015-10-2335 citations

Exposure-Response Analyses for Tafenoquine after Administration to Patients with Plasmodium vivax Malaria

Antimicrobial Agents and Chemotherapy2015-07-2814 citations

Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.

2013-12-19202 citations